nach oben

Journal of Neuro-Oncology

Erschienen in:

01.03.2011 | Laboratory Investigation - Human/Animal Tissue

Epo is involved in angiogenesis in human glioma

verfasst von: Beatrice Nico, Tiziana Annese, Diego Guidolin, Nicoletta Finato, Enrico Crivellato, Domenico Ribatti

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

In this study, the extent of angiogenesis, evaluated as microvascular density, and the immunoreactivity of tumor cells to erythropoietin (Epo) and of endothelial cells to Epo receptor (EpoR) have been correlated in human glioma specimens, and the effect of anti-Epo antibody on glioma-induced angiogenesis in vivo in the chick embryo chorioallantoic membrane (CAM) has been investigated. Results show that: (1) Epo/EpoR expression correlates with angiogenesis, (2) in the CAM assay, tumor bioptic specimens induce a strong angiogenic response, comparable to that induced by VEGF, and (3) an anti-Epo antibody co-administered with tumor bioptic specimens significantly inhibits the angiogenic response. These findings suggest the presence of a loop in the Epo/EpoR system, i.e. Epo is secreted by glioma tumor cells and it affects glioma vascular endothelial cells via its receptor and promotes angiogenesis in a paracrine manner. Moreover, as demonstrated by in vivo experiments, Epo is responsible for the strong angiogenic response induced by human glioma bioptic specimens, because an anti-Epo antibody is able to significantly inhibit this response.

Kleinhues P, Cavenee W (2000) Astrocytic tumors. In: Pathology and genetics of tumors of the nervous system. World Health Organization Classification of Tumours. ISN Neuropath Press, Basel, pp 9–52

Machein MR, Plate KH (2000) VEGF in brain tumors. J Neurooncol 50:109–120CrossRefPubMed

Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297–310CrossRefPubMed

Bernsen HJJA, Rijken PFJW, Peters JPW, Bakker H, van der Kogel A (1998) Delayed vascular changes after antiangiogenic therapy with anti-vascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Neurosurgery 43:570–575CrossRefPubMed

Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314CrossRefPubMed

Chamberlain MC (2008) Antiangiogenesis: biology and utility in the treatment of gliomas. Expert Rev Neurother 8:1419–1423CrossRefPubMed

Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG (2002) Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 9:24–36CrossRefPubMed

Nir I, Kohn S, Doron Y, Israel O, Front D (1986) Quantitative analysis of tight junctions and the uptake of 99mTc in human gliomas. Cancer Invest 4:519–524CrossRefPubMed

Dinda AK, Sarkar C, Roy S, Kharbanda K, Mathur M, Khosla AK, Banerji AK (1993) A transmission and scanning electron microscopic study of tumoral and peritumoral microblood vessels in human gliomas. Neurooncology 16:149–158CrossRef

10.

Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, Wolburg H (2000) Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 100:323–331CrossRefPubMed

11.

Rascher G, Fischmann A, Kröger S, Duffner F, Grote EH, Wolburg H (2002) Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol 104:85–91CrossRefPubMed

12.

Ribatti D (2008) Erythropoietin, the first century. Leuk Res 32:1169–1172CrossRefPubMed

13.

Ribatti D (2010) Erythropoietin and tumor angiogenesis. Stem Cells Dev 19:1–4CrossRefPubMed

14.

Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635–4640CrossRefPubMed

15.

Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643–651CrossRefPubMed

16.

Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526–10531CrossRefPubMed

17.

Sirén AL, Radyushkin K, Boretius S, Kammer D, Riechers CC, Natt O, Sargin D, Watanabe T, Sperling S, Michaelis T, Price J, Meyer B, Frahm J, Ehrenreich H (2006) Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain 129:480–489CrossRefPubMed

18.

Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, Sirén AL, Paulus W, Nave KA, Gold R, Bartels C (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130:2577–2588CrossRefPubMed

19.

Ehrenrecich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495–505

20.

Yin D, Kawabata H, Tcherniamtchouk O, HuynH T, Black KL, Koeffler HP (2007) Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin. Int J Oncol 31:1193–1198PubMed

21.

Krieg M, Marti HH, Plate KH (1998) Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 92:3388–3393PubMed

22.

Said HM, Hagermann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K, Vordermark D (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1α in human glioma in vitro and in vivo. Radiother Oncol 83:398–405CrossRefPubMed

23.

Mittelbronn M, Capper D, Bunz B, Dietz K, Goeppert B, Ajaaj R, Tabatabai G, Stubenvoll F, Schlaszus H, Merseburger AS, Becker R, Freudenstein D, Wick W, Weller M, Mayermann R, Simon P (2007) De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol 33:299–307CrossRefPubMed

24.

Wang L, Zhang Z, Wang Y, Zhang R, Chopp M (2004) Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35:1732–1737CrossRefPubMed

25.

Ribatti D (2010) The chick embryo chorioallantoic membrane in the study of angiogenesis and metastasis. Springer, BerlinCrossRef

26.

Kelinhues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3:255–268CrossRef

27.

Elias H, Hyde DM (eds) (1983) Stereological measurements of isotropic structures. In: A guide to practical stereology. Basel, Karger, pp 22–44

28.

Guidolin D, Zunarelli E, Genedani S, Trentini GP, De Gaetani C, Fuxe K, Benagiano C, Agnati LF (2008) Opposite patterns of age-associated changes in neurons and glial cells of the thalamus of human brain. Neurobiol Aging 29:926–936CrossRefPubMed

29.

Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD, Kalra VK, Malik P (2003) Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 102:1506–1514CrossRefPubMed

30.

Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26:132–149CrossRefPubMed

31.

Kayser K, Gabius HJ (1992) Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentrabl Pathol 138:266–270

32.

Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58:647–657CrossRefPubMed

33.

Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagao M, Sasaki R, Nakamura Y (2001) Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84:836–843CrossRefPubMed

34.

Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y (2002) Erythropoietin is involved in growth and angiogenesis in malignant tumors of female reproductive organs. Carcinogenesis 23:1797–1805CrossRefPubMed

35.

Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162:1789–1806CrossRefPubMed

36.

Batra S, Perelman N, Luck LR, Shimada H, Malik P (2003) Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477–1487CrossRefPubMed

37.

Hengartner MO, Horvitz HR (1994) C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76:665–676CrossRefPubMed

38.

Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A (2002) Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95:969–981CrossRefPubMed

39.

Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA (2002) Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82:911–918PubMed

40.

Dillard DG, Venkatraman G, Cohen C, Delgaudio J, Gal AA, Mattox DE (2001) Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol 121:149–152CrossRefPubMed

41.

Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021–1029CrossRefPubMed

42.

Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H (2008) Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10:932–939PubMed

43.

Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, Vujaskovic Z, Dewhirst MW, Arcasoy MO (2007) Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2:e549CrossRefPubMed

44.

Olujohungbe A, Handa S, Holmes J (1987) Do erythropoietin accelerate malignant transformation in multiple myeloma? Postgrad Med J 73:163–164CrossRef

45.

Bunworasate U, Arnouk H, Mindermal H, O’Loughlin KL, Sait SN, Barcos M, Stewart CC, Baer MR (2001) Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 98:3492–3494CrossRefPubMed

46.

Ribatti D (2002) A potential role of erythropoietin in angiogenesis associated with myelodysplastic syndromes. Leukemia 16:1890CrossRefPubMed

47.

Crivellato E, Nico B, Vacca A, Djonov V, Presta M, Ribatti D (2004) Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia 18:331–336CrossRefPubMed

48.

Nico B, Crivellato E, Guidolin D, Annese T, Annese T, Longo V, Finato N, Vacca A, Ribatti D (2010) Intussusceptive microvascular growth in human glioma. Clin Exp Med 10:93–98CrossRefPubMed

Titel: Epo is involved in angiogenesis in human glioma
verfasst von: Beatrice Nico
Tiziana Annese
Diego Guidolin
Nicoletta Finato
Enrico Crivellato
Domenico Ribatti
Publikationsdatum: 01.03.2011
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2011
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0294-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Clinical characteristics and treatment of ectopic meningiomas

Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas

Clinical emergence of neurometastatic merkel cell carcinoma: a surgical case series and literature review

Identification of diagnostic serum protein profiles of glioblastoma patients

Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53